Literature DB >> 16565581

Skull base chordomas: management and results.

Carsten Stüer1, Johannes Schramm, Carlo Schaller.   

Abstract

Growth patterns of skull base chordomas are related to important neurovascular structures. Local invasiveness results in "clinically malignant" behavior. A high rate of transient neurological deficits occurs following radical surgery. At our institution, the principle of radical removal is not followed at any price. This study compared the results of our management with recent series. Eleven patients, five females and six males aged 24-65 years (mean 41 years), underwent removal of skull base chordoma with size one <3 cm, five 3-5 cm, and five >5 cm. Mostly, standard operative approaches were chosen. All patients underwent postoperative radiotherapy. Resection was subtotal/partial in seven patients and total in four with no mortality. Neurological deterioration occurred due to transient cranial nerve deficits in six patients. Temporary surgical morbidity (including cranial nerve deficits) was observed in seven patients. Median Karnofsky performance status score improved compared to preoperative (80), early postoperative (70), and latest assessment (90) (median 36 months). Five patients underwent reoperation due to tumor recurrence after 4-48 months (mean 24 months). Most patients undergoing removal of skull base chordomas suffer from transient neurological deficits which are mainly nonsignificant as the patients return to preoperative functional status. The apparently high rate of incomplete tumor resection (64%) reflects the infiltrative behavior and relationship with neurovascular structures. The operative strategy should not be excessively aggressive at any price, but rather take into account the options of radiotherapy and observation of residual tumor.

Entities:  

Mesh:

Year:  2006        PMID: 16565581     DOI: 10.2176/nmc.46.118

Source DB:  PubMed          Journal:  Neurol Med Chir (Tokyo)        ISSN: 0470-8105            Impact factor:   1.742


  8 in total

Review 1.  Current therapeutic options and novel molecular markers in skull base chordomas.

Authors:  Filippo Gagliardi; Nicola Boari; Paola Riva; Pietro Mortini
Journal:  Neurosurg Rev       Date:  2011-10-18       Impact factor: 3.042

2.  MR Imaging Grading System for Skull Base Chordoma.

Authors:  K Tian; L Wang; J Ma; K Wang; D Li; J Du; G Jia; Z Wu; J Zhang
Journal:  AJNR Am J Neuroradiol       Date:  2017-04-20       Impact factor: 3.825

3.  Treatment and Outcome of Patients with Skull Base Chordoma: A Meta-analysis.

Authors:  Moran Amit; Shorook Na'ara; Yoav Binenbaum; Salem Billan; Gil Sviri; Jacob T Cohen; Ziv Gil
Journal:  J Neurol Surg B Skull Base       Date:  2014-05-27

4.  Intracranial chordoma: radiosurgery, hypofractionated stereotactic radiotherapy and treatment outcomes.

Authors:  Aleksandra Napieralska; Sławomir Blamek
Journal:  Rep Pract Oncol Radiother       Date:  2021-09-30

5.  Spinal column chordoma: prognostic significance of clinical variables and T (brachyury) gene SNP rs2305089 for local recurrence and overall survival.

Authors:  Chetan Bettegowda; Stephen Yip; Sheng-Fu Larry Lo; Charles G Fisher; Stefano Boriani; Laurence D Rhines; Joanna Y Wang; Aron Lazary; Marco Gambarotti; Wei-Lien Wang; Alessandro Luzzati; Mark B Dekutoski; Mark H Bilsky; Dean Chou; Michael G Fehlings; Edward F McCarthy; Nasir A Quraishi; Jeremy J Reynolds; Daniel M Sciubba; Richard P Williams; Jean-Paul Wolinsky; Patricia L Zadnik; Ming Zhang; Niccole M Germscheid; Vasiliki Kalampoki; Peter Pal Varga; Ziya L Gokaslan
Journal:  Neuro Oncol       Date:  2017-03-01       Impact factor: 12.300

Review 6.  Adjuvant radiation therapy and chondroid chordoma subtype are associated with a lower tumor recurrence rate of cranial chordoma.

Authors:  Brian J Jian; Orin G Bloch; Isaac Yang; Seunggu J Han; Derick Aranda; Tarik Tihan; Andrew T Parsa
Journal:  J Neurooncol       Date:  2009-12-02       Impact factor: 4.130

7.  Multidisciplinary management of clival chordomas; long-term clinical outcome in a single-institution consecutive series.

Authors:  Petter Förander; Jiri Bartek; Michael Fagerlund; Hamza Benmaklouf; Ernest Dodoo; Alia Shamikh; Pär Stjärne; Tiit Mathiesen
Journal:  Acta Neurochir (Wien)       Date:  2017-07-22       Impact factor: 2.216

8.  Clival chordoma: long-term clinical outcome in a single center.

Authors:  Yibiao Zhou; Bolin Hu; Zhiwei Wu; Hanxiong Cheng; Min Dai; Bin Zhang
Journal:  Medicine (Baltimore)       Date:  2018-09       Impact factor: 1.817

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.